(32) In a simplified humanized murine model of CRS/neurotoxicity after treatment with anti-CD19 CAR T, treatment with the IFN-ɣ inhibitor emapalumab led to decreased inflammatory signaling and toxicity mitigation without impacting CAR T efficacy. The gene discussed is CD19; the disease is congenital rubella syndrome.